A life science CDMO is investing hundreds of millions of dollars into manufacturing nucleic acids amid increasing demand for active pharmaceutical ingredients, or API.
Agilent Technologies, which spun out of American tech giant Hewlett Packard back in 1999, put the word out on Monday, saying that the $725 million will be used to double the company’s current manufacturing capacity for therapeutic nucleic acids. These nucleic acids, also known as therapeutic oligonucleotides, are DNA or RNA molecules that act as the API for certain drugs that target indications such as cancer or rare diseases.
Agilent said that the expansion will specifically meet the growing demand for siRNA, antisense and CRISPR guide RNA molecules.
CEO Mike McMullen said in a statement that the investment is a reflection of “strong demand” for therapeutic oligonucleotides. The company added that the market for therapeutic oligos is estimated…
Click here to view original post
